Two FDA actions topped ophthalmology news in November, with an approval for the MiSight contact lens and an orphan drug designation for ProQR’s retinitis pigmentosa treatment.
Here are the top five most-read articles on Healio/OSN last month:
FDA approves MiSight contact lens to slow myopia progression in children
The MiSight contact lens (CooperVision) is a disposable, soft lens that is limited for one-time use and is not for wearing overnight. Read more.
ProQR’s retinitis pigmentosa treatment gets orphan drug designation
QR-1123, a first-in-class investigational antisense
Uncategorized